Smithkline Corporation

Smithkline Beckman Corporation

Smithkline Beecham Corporation

Carl D Perchonock

John G Gleason

Paul E Bender

Ralph F Hall

Thomas Wen-Fu Ku

Jerry Leroy Adams

Bernard Loev

Nabil Hanna

John F Newton

Kenneth G Holden

William G Groves

Kazys A Razgaitis

Compounds comprising pyridyl and phenyl substituted pyrrolo[1,2-a]imidazole derivatives and pyridyl and phenyl substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions containing said compounds, and their use as 5-lipoxygenase pathway inhibitors.

Pyrrolo [1,2-a] imidazole and imidazo [1,2a] pyridine derivatives and

Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their

This invention relates to alkanoic acid compounds having phenyl and thio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

This invention relates to alkanoic acid compounds having phenyl and thio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Thiophenyl Alkanoic acids useful as leukotriene antagonists

The compounds represented by the following structural formula (I) ##STR1## wherein m is 1 or 2; n is 1, 2 or 3; R' is hydrogen or methyl; R is a radical selected from the group consisting of: ##STR2## wherein R.sub.1 is C.sub.8 to C.sub.13 alkyl, C.sub.7 to C.sub.12 alkoxy, C.sub.7 to C.sub.12 thioalkyl, C.sub.10 to C.sub.12 1-alkynyl, 11-dodecynyl, 1-trans-dodecenyl, 5-(4-acetyl-3-hydroxy-2-propylphenoxypentoxy, 2(Z), 5(Z)-undecadienyloxy, phenyl-C.sub.4 to C.sub.10 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, methoxy, methylthio or trifluoromethylthio, phenylthio-C.sub.3 to C.sub.9 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, methoxy, methylthio or trifluoromethylthio, phenyl-CH.dbd.CH--(CH.sub.2).sub.2-8, phenyl-C.sub.3 to C.sub.9 alkoxy, trifluoromethyl-C.sub.7 to C.sub.12 alkyl, cyclohexyl- C.sub.4 to C.sub.10 alkyl or ##STR3## wherein each q is 0, 1, 2 or 3 but the sum of both q's does not exceed 3, and R.sub.2 is hydrogen, bromo, chloro, methyl, trifluoromethyl, hydroxy, methoxy or nitro; or R.sub.1 is hydrogen and R.sub.2 is C.sub.8 to C.sub.13 alkyl, C.sub.7 to C.sub.12 alkoxy, C.sub.7 to C.sub.12 thioalkyl, C.sub.10 to C.sub.12 1-alkynyl, 11-dodecynyl, 1-trans-dodecenyl, 5-(4-acetyl-3-hydroxy-2-propylphenoxy(pentoxy, 2(Z), 5(Z)-undecadienyloxy, phenyl-C.sub.4 to C.sub.10 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, methoxy, methylthio or trifluoromethylthio, phenylthio-C.sub.3 to C.sub.9 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, methoxy, methylthio or trifluoromethylthio, phenyl-CH.dbd.CH--(CH.sub.2).sub.2-8, phenyl-C.sub.3 to C.sub.9 alkoxy, trifluoromethyl-C.sub.7 to C.sub.12 alkyl, cyclohexyl-C.sub.4 to C.sub.10 alkyl or ##STR4## wherein each q is 0, 1, 2 or 3 but the sum of both q's does not exceed 3, and p is 0 or 1, with the proviso that R is not a thiophene radical and any of R.sub.1 and R.sub.2 above are not thioalkyl or phenylthioalkyl when p is 1; and pharmaceutically acceptable salts thereof have been found to be leukotriene antagonists and useful in the treatment of diseases in which leukotrienes are a factor, such as asthma.

Leukotriene antagonist

The compounds represented by the following structural formula (I) ##STR1## wherein m and n are independently 1, 2 or 3; R.sub.1 is an C.sub.8 to C.sub.13 alkyl radical and pharmaceutically acceptable salts thereof have been found to be leukotriene antagonists and useful in the treatment of diseases in which leukotrienes are a factor, such as asthma.

A novel process for preparing 7,8-dichloro-1,2,3,4-tetrahydroisoquinoline by cyclizing N-acetyl-2,3-dichlorobenzylaminoacetaldehyde dimethyl acetal with a Lewis acid, reducing, and hydrolyzing the resulting acylated isoquinoline is disclosed.

Method for preparing 7,8-dichloro-1,2,3,4-tetrahydroisoquinoline

A new compound with a nucleus containing a benzo-fused carbocyclic .beta.-lactam system is disclosed. The compound has antibacterial activity against B. subtilis.

Tricyclic (azeto-isoquinoline) .beta.-lactams

A new .beta.-lactam system containing a tricyclic ring nucleus is disclosed. In addition to the .beta.-lactam, the new nucleus contains a cyclic hydrazide moiety. The compounds have antibacterial activity.

Tricyclic .beta.-lactams

Aromatic prostaglandin derivatives are prepared. These compounds have valuable antiprostaglandin activity specifically inhibiting prostaglandin synthesis and antagonizing diarrhea induced by prostaglandin E.sub.2 (PGE.sub.2).

Aromatic prostaglandin derivatives

9-Xanthylaminoalkylpyridine derivatives are prepared. These compounds are inhibitors of gastric acid secretion.

Growing community of inventors

Philadelphia, PA, United States of America

Carl D Perchonock